Alice Garnier

Nantes, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 88 publications

Treosulfan or busulfan plus clofarabine as reduced intensity conditioning regimen before allotransplant for adults with myeloid malignancies.

Treosulfan or busulfan plus clofarabine as reduced intensity conditioning regimen before allotransplant for adults with myeloid malignancies.

Journal: Bone marrow transplantation

Published: May 19, 2026

Functional recovery of NK cells after T-cell replete haploidentical HSCT: delayed licensing and poor anti-acute myeloid leukemia activity.

Functional recovery of NK cells after T-cell replete haploidentical HSCT: delayed licensing and poor anti-acute myeloid leukemia activity.

Journal: Blood advances

Published: July 08, 2025

Comparative Efficacy and Safety of Anakinra and Canakinumab in Patients With VEXAS Syndrome: An International Multicenter Study.

Comparative Efficacy and Safety of Anakinra and Canakinumab in Patients With VEXAS Syndrome: An International Multicenter Study.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: May 13, 2025

Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, single-arm, phase 2 trial.

Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, single-arm, phase 2 trial.

Journal: The Lancet. Haematology

Published: March 24, 2025

A phase II study of ponatinib for prevention of relapse after allogeneic transplantation in FLT3 internal tandem duplication mutation-positive (FLT3-ITD+) acute myeloid leukemia: the PONALLO trial.

A phase II study of ponatinib for prevention of relapse after allogeneic transplantation in FLT3 internal tandem duplication mutation-positive (FLT3-ITD+) acute myeloid leukemia: the PONALLO trial.

Journal: Haematologica

Published: February 27, 2025

Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS.

Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS.

Journal: Blood advances

Published: February 24, 2025

Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX.

Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX.

Journal: Blood

Published: February 11, 2025

Thiotepa-busulfan-fludarabine compared to clofarabine-based conditioning for haploidentical transplant with posttransplant cyclophosphamide in patients with myeloid malignancies: a retrospective study from the SFGM-TC.

Thiotepa-busulfan-fludarabine compared to clofarabine-based conditioning for haploidentical transplant with posttransplant cyclophosphamide in patients with myeloid malignancies: a retrospective study from the SFGM-TC.

Journal: Bone marrow transplantation

Published: February 06, 2025

Molecular Interactions Between NK Cells and Acute Leukemic Cells: KIR2DL5 Drastically Limits NK Cell Responses.

Molecular Interactions Between NK Cells and Acute Leukemic Cells: KIR2DL5 Drastically Limits NK Cell Responses.

Journal: Journal of clinical immunology

Published: January 27, 2025

Posaconazole versus fluconazole as primary antifungal prophylaxis for patients at high risk of invasive fungal infections receiving allogeneic hematopoietic stem cell transplantation.

Posaconazole versus fluconazole as primary antifungal prophylaxis for patients at high risk of invasive fungal infections receiving allogeneic hematopoietic stem cell transplantation.

Journal: Bone marrow transplantation

Published: October 18, 2024

Pre-graft vaccination or infection do not decrease COVID-19 infections in recipients of allogeneic stem cell transplantation vaccinated and/or protected by immunotherapy after transplant.

Pre-graft vaccination or infection do not decrease COVID-19 infections in recipients of allogeneic stem cell transplantation vaccinated and/or protected by immunotherapy after transplant.

Journal: Human vaccines & immunotherapeutics

Published: July 08, 2024

Deep Learning-Based Blood Abnormalities Detection as a Tool for VEXAS Syndrome Screening.

Deep Learning-Based Blood Abnormalities Detection as a Tool for VEXAS Syndrome Screening.

Journal: International journal of laboratory hematology

Published: March 26, 2024

Showing 1-12 of 88

Last Updated: 09/26/2026